Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.40-$2.50 vs $2.45 Est; Lowers FY2026 Sales Guidance from $1.662B-$1.702B to $1.65

Integra Lifesciences (NASDAQ: IART ) affirms FY2026 Adj EPS guidance from $2.40-$2.50 to $2.40-$2.50 vs $2.45 analyst estimate. Lowers FY2026 sales outlook from $1.662 billion-$1.702 billion to $1.654 billion-$1.695 billion vs $1.676 billion estimate.